Compare · A vs HTGM
A vs HTGM
Side-by-side comparison of Agilent Technologies Inc. (A) and HTG Molecular Diagnostics Inc. (HTGM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and HTGM operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $41.39B, about 1953.4x HTGM ($21.2M).
- A has hit the wire 2 times in the past 4 weeks while HTGM has been quiet.
- A has more recent analyst coverage (25 ratings vs 1 for HTGM).
- Company
- Agilent Technologies Inc.
- HTG Molecular Diagnostics Inc.
- Price
- $115.53+1.05%
- $0.48-21.22%
- Market cap
- $41.39B
- $21.2M
- 1M return
- +2.27%
- -
- 1Y return
- +8.07%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- 2015
- News (4w)
- 2
- 0
- Recent ratings
- 25
- 1
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
HTG Molecular Diagnostics Inc.
HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Latest A
- Agilent Showcases Cancer Research Solutions at AACR 2026
- Amendment: Agilent Technologies Inc. filed SEC Form 8-K: Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits
- Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Henson Meghan
- Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
- Amendment: SEC Form SCHEDULE 13G/A filed by Agilent Technologies Inc.
- Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
- SEC Form 4 filed by Rataj Sue H.
- SEC Form 4 filed by Brawley Otis W
- SEC Form 4 filed by Scangos George A
Latest HTGM
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Why Asset Entities Shares Are Trading Higher By 142%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- SEC Form 4 filed by Barat Stephen
- HTG Molecular Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Lows On Tuesday
- Why Are HTG Molecular Diagnostics Shares Plunging Today
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Why THOR Industries Shares Are Trading Higher By 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session